MIPSAGARGIN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C66H100N6O27
Molecular Weight	1409.5242
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCC(=O)O[C@@H]1[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]3OC(=O)[C@@](C)(O)[C@@]3(O)[C@H](C[C@](C)(OC(C)=O)[C@@H]12)OC(=O)CCCCCCCCCCCNC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C(O)=O

InChI

InChIKey=UPYNTAIBQVNPIH-ODMLWHIESA-N

InChI=1S/C66H100N6O27/c1-8-10-11-17-20-24-51(81)96-55-53-52(37(4)54(55)97-62(91)36(3)9-2)56-66(94,65(7,93)63(92)98-56)44(35-64(53,6)99-38(5)73)95-50(80)23-21-18-15-13-12-14-16-19-22-33-68-48(77)34-39(67)57(82)72-43(61(89)90)27-31-47(76)70-41(59(85)86)25-29-45(74)69-40(58(83)84)26-30-46(75)71-42(60(87)88)28-32-49(78)79/h9,39-44,53-56,93-94H,8,10-35,67H2,1-7H3,(H,68,77)(H,69,74)(H,70,76)(H,71,75)(H,72,82)(H,78,79)(H,83,84)(H,85,86)(H,87,88)(H,89,90)/b36-9-/t39-,40-,41-,42-,43-,44-,53+,54-,55-,56-,64-,65+,66+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C66H100N6O27
Molecular Weight	1409.5242
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	13 / 13
E/Z Centers	3
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25856061 | https://clinicaltrials.gov/ct2/show/NCT01777594 | https://clinicaltrials.gov/ct2/show/NCT02067156 | https://phytonbiotech.com/patent-application-for-genspera-partner-phyton-biotech-is-published-by-world-intellectual-property-organization-wipo/

Inspyr Therapeutics (formerly GenSpera) developed mipsagargin (previously known as G-202), as a novel thapsigargin-based targeted prodrug that is activated by prostate-specific membrane antigen (PSMA)-mediated cleavage of an inert masking peptide. The active moiety is an inhibitor of the sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump protein that is necessary for cellular viability. Mipsagargin was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma. In addition, mipsagargin has been studied in phase 2 clinical trial in patients with recurrent or progressive glioblastoma, in patients with clear cell renal cell carcinoma that expresses PSMA. Mipsagargin is expected to be launched on the market in the coming years.

Originator

Approval Year

PubMed

Title	Date	PubMed
Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.	2016-04-26	27115568
Thapsigargin--from Thapsia L. to mipsagargin.	2015-04-08	25856061

Sample Use Guides

In Vivo Use Guide

G-202 (Mipsagargin) administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:58:58 GMT 2025` Edited by `admin` on `Mon Mar 31 21:58:58 GMT 2025`
Record UNII	Q032I35QMX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

mipsagargin [INN]

Preferred Name

English

MIPSAGARGIN

Official Name

English

Mipsagargin [WHO-DD]

Common Name

English

MIPSAGARGIN [USAN]

Common Name

English

G-202

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

389613